Phase I, Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-Linking Agent, in advanced solid tumors

PURPOSE: This phase I study assessed the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of SJG-136, a sequence-specific DNA cross-linking agent, in patients with advanced cancer. EXPERIMENTAL DESIGN: In Schedule A, seven patients received escalati...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Puzanov, Igor, Lee, Wooin, Chen, Alice P., Calcutt, M. Wade, Hachey, David. L., Vermeulen, Wendy L., Spanswick, Victoria J., Liao, Chih-Yi, Hartley, John A., Berlin, Jordan D., Rothenberg, Mace L.
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3107910/
https://ncbi.nlm.nih.gov/pubmed/21346148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2056
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items